This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck and is provided by The American Association of Nurse Practitioners in collaboration with Haymarket Medical Education (HME).
Charles L. Raison, MD
School of Human Ecology
Department of Psychiatry, School of Medicine and Public Health
University of Wisconsin-Madison
Catherine R. Judd, MS, PA-C
Clinical Assistant Professor
Southwestern School of Health Professions
Department of Physician Assistant Studies
Parkland Health & Hospital System
Behavorial and Mental Health Services
Cindy Parsons, DNP, ARNP-BC, FAANP
Associate Professor of Nursing
University of Tampa
Sattaria S. Dilks, DNP, APRN, PMHNP-BC, FAANP
Professor and Co-Coordinator, Graduate Program
College of Nursing, McNeese State University
Lake Charles, La.
Release Date: October 15, 2015
Expiration Date: October 15, 2016
Estimated time to complete the educational activity: 60 minutes
Statement of Need: Major depressive disorder (MDD) is a disturbance of mood that may persist and have long-term consequences impacting patients’ overall level of functioning and quality of life.1 Current treatment guidelines for major depressive disorder (MDD) recommend an end goal of full remission; however, few patients with MDD receive any treatment, receive adequate treatment, or achieve full remission. This educational activity will provide primary care nurse practitioners (NPs)—who are key components of the collaborative care team for MDD and are often responsible for monitoring treatment response—with an understanding of the impact of residual symptoms and the utilization of validated tools for monitoring treatment response; a review of novel treatment approaches; and strategies that support patient-provider communication.
Target Audience: This activity is intended for nurse practitioners who treat patients with MDD.
Learning Objectives: After completing the activity, the participant should be better able to:
- Review the impact of residual major depressive disorder (MDD) symptoms on patient function, quality of life, and long-term outcomes
- Utilize measurement-based care tactics to effectively monitor and assess symptom resolution in patients receiving therapy for MDD
- Apply recommended strategies, as set forth by the American Psychiatric Association (APA), in modifying MDD treatment to achieve long-term remission in nonresponders or partial responders to therapy
- Identify patients with MDD who might benefit from new pharmacologic treatment options, while considering safety and efficacy parameters
- Employ the shared decision-making (SDM) model to foster communication between MDD patients and their healthcare providers
Conflict of Interest: It is the policy of the American Association of Nurse Practitioners to require all faculty to provide disclosure of any financial relationship within the past 12 months with a commercial interest or any commercial product discussed in an educational presentation. All real or potential conflicts of interest identified must be resolved prior to program development and approval.
Accreditation Statement: This program was planned in accordance with the AANP Accreditation Standards and Policies.
Credit Designation Statement: This program is approved for 1.0 contact hours of continuing education by the American Association of Nurse Practitioners.
The faculty reported the following financial relationships or relationships to products or devices they have with commercial interests related to the content of this CE activity:
Charles L. Raison, MD, is a consultant for Otsuka and Pamlab. He serves on the speakers bureaus for Otsuka, Pamlab, and Sunovion. Dr. Raison’s spouse is an employee of Transdermal Therapeutics.
Catherine R. Judd, MS, PA-C, has no relevant financial relationships to disclose.
Cindy Parsons, DNP, ARNP-BC, FAANP, has no relevant financial relationships to disclose.
Sattaria S. Dilks, DNP, APRN, PMHNP-BC, FAANP, has no relevant financial relationships to disclose.
Sylvia Nashed, PharmD, Krista Sierra, Susan Basilico, and Java Solis of HME have no financial relationships to disclose.
Anne Norman, DNP, APRN, FNP-BC, and Michele McKay, MSN, APRN, FNP-C, of AANP have nothing to disclose with regard to commercial support.
Method of Participation: There are no fees for participating in and receiving CME/CE credit for this activity. During the period of October 10, 2015, through October 10, 2016, participants must:
- Read the learning objectives and faculty disclosures;
- Study the educational activity;
- Submit the post-test online (clinicians may register at www.mycme.com).
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclaimer: The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.